InvestorsHub Logo
Followers 21
Posts 1676
Boards Moderated 0
Alias Born 07/09/2005

Re: None

Tuesday, 06/04/2019 1:10:23 PM

Tuesday, June 04, 2019 1:10:23 PM

Post# of 335
The company is optimistic.

"We believe the new in vitro data generated was encouraging, and the FDA was helpful with guidance regarding data needed to move forward in type 2 diabetes," Zafgen CEO Jeffrey Hatfield said in a statement.

What's Next

Zafgen said it is evaluating serious, rare disease indications for which ZGN-1061 could be useful.

The FDA was supportive of Zafgen seeking guidance on a second investigational new drug application for ZGN-1061 as appropriate.

Zafgen is set to provide an update on development plans by the end of the third quarter.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent LRMR News